Breaking News

Almac Completes Commercial API Facility

October 9, 2012

Will be operational by the end of the year

Almac’s expansion of its API manufacturing facility at its European Headquarters in Craigavon, UK has been completed and will be operational by the end of the year.  The expansion includes the installation of two 1,000L reactors and pressure filter dryer, which allows production of GMP API to 150kg batch size.
“Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development,” said Denis Geffroy, vice president of business development. “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialization.”
The expansion allows clients to leverage Almac’s API and drug product offering at the same site, allowing technology transfer of small molecule and peptide projects from lab development to large-scale manufacture.

Related Contract Manufacturing:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus